Therefore, targeting STAT3 by small molecule inhibitor FLLL32 could be a potential therapeutic strategy for inhibiting pancreatic cancer progression and overcoming chemo/radio-resistance. This evidence concerns the gene STAT3 and pancreatic neoplasm.